AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7588990 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Apomorphine
Number of subjects: 7
Study 2134545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy cardiovasoprotective (CVP) diet (Group A)
Number of subjects: 416
Study 2134545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy usual diet (Group B)
Number of subjects: 416
Study 2134545 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal-energy CVP diet (Group C)
Number of subjects: 416
Study 2134545 — intervention group
Group type: COMPARATOR
Intervention: Optimal-energy, usual pre-experimental diet (Group D)
Number of subjects: 416
Study 6958479 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 divided doses of BDP
Number of subjects: 29
Study 6958479 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of BDP
Number of subjects: 29
Study 31992545 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish Knee Control programme and standard running warm-up before every training session and match during the season
Number of subjects: 471
Study 31992545 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish Knee Control programme
Number of subjects: 471
Study 31992545 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual training)
Number of subjects: 471
Study 31729976 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified catheter (Group C)
Number of subjects: 90
Study 31729976 — intervention group
Group type: COMPARATOR
Intervention: Conventional tracheal intubation without endotracheal anesthesia (Group A)
Number of subjects: 90
Study 31729976 — intervention group
Group type: COMPARATOR
Intervention: Conventional tracheal intubation with endotracheal anesthesia (Group B)
Number of subjects: 90
Study 28801940 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month lifestyle (diet and exercise) weight loss intervention
Number of subjects: 70
Study 26441396 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) defined as post‐tetanic‐count (PTC) of 0‐1
Number of subjects: 128
Study 26441396 — intervention group
Group type: COMPARATOR
Intervention: Standard neuromuscular blockade defined as bolus administrations
Number of subjects: 128
Study 26441396 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB)
Number of subjects: 128
Study 23418444 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intensity physical activity (walking and standing)
Number of subjects: 18
Study 23418444 — intervention group
Group type: COMPARATOR
Intervention: Sitting regime
Number of subjects: 18
Study 23418444 — intervention group
Group type: COMPARATOR
Intervention: Exercise regime (vigorous exercise)
Number of subjects: 18
Study 21548919 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based cognitive behavioral multidisciplinary lifestyle treatment
Number of subjects: 80
Study 21548919 — intervention group
Group type: COMPARATOR
Intervention: Advice on physical activity and nutrition (Control)
Number of subjects: 80
Study 19497458 — intervention group
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Number of subjects: 165
Study 19497458 — intervention group
Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 165
Study 17695877 — intervention group
Group type: EXPERIMENTAL
Intervention: Glazed surfaces
Number of subjects: 2
Study 17695877 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished surfaces
Number of subjects: 2
Study 17695877 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing on glazed surfaces
Number of subjects: 2
Study 17695877 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing on polished surfaces
Number of subjects: 2
Study 17695877 — intervention group
Group type: COMPARATOR
Intervention: Comparison between glazed and polished surfaces after 1 hour
Number of subjects: 2
Study 16682575 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medical record alerts for coprescription of warfarin and interacting medications (acetaminophen, nonsteroidal anti‐inflammatory medications, fluconazole, metronidazole, sulfamethoxazole)
Number of subjects: 9910
Study 16682575 — intervention group
Group type: COMPARATOR
Intervention: Group academic detailing
Number of subjects: 9910
Study 15173406 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (weekly home visits from birth to 8 weeks and from 7 to 24 months)
Number of subjects: 140
Study 15173406 — intervention group
Group type: COMPARATOR
Intervention: Control group (LBW infants without intervention)
Number of subjects: 140
Study 10739153 — intervention group
Group type: EXPERIMENTAL
Intervention: In-shoe plantar pressure measurement system
Number of subjects: 14
Study 8737627 — intervention group
Group type: COMPARATOR
Intervention: 0.250 mg brotizolam
Number of subjects: 49
Study 8737627 — intervention group
Group type: COMPARATOR
Intervention: 0.125 mg brotizolam
Number of subjects: 49
Study 8737627 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (0.125 mg and 0.250 mg brotizolam)
Number of subjects: 49
Study 1560699 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 40% idoxuridine in dimethyl sulfoxide (IDU)
Number of subjects: 171
Study 1560699 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir (ACV)
Number of subjects: 171
Study 3840882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous furosemide (2 mg/kg)
Number of subjects: 6
Study 3840882 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled atropine sulfate (0.05 mg/kg)
Number of subjects: 6
Study 3840882 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isoproterenol (0.2 cc, 1:200)
Number of subjects: 6
Study 3840882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31868850 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 39
Study 31868850 — intervention group
Group type: COMPARATOR
Intervention: LASEK
Number of subjects: 39
Study 31868850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 30445893 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted patient education
Number of subjects: 107
Study 30445893 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 107
Study 30445893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107
Study 28012977 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage IBBR with ADM
Number of subjects: 142
Study 28012977 — intervention group
Group type: COMPARATOR
Intervention: Two-stage IBBR
Number of subjects: 142
Study 28012977 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 142
Study 25887231 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0
Study 25887231 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training
Number of subjects: 0
Study 23075634 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil and morphine (Group AM)
Number of subjects: 212
Study 23075634 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (Group F)
Number of subjects: 212
Study 21593417 — intervention group
Group type: EXPERIMENTAL
Intervention: Line drawings
Number of subjects: 0
Study 21593417 — intervention group
Group type: COMPARATOR
Intervention: Color photographs
Number of subjects: 0
Study 21593417 — intervention group
Group type: EXPERIMENTAL
Intervention: Line drawings with long contours removed
Number of subjects: 0
Study 21593417 — intervention group
Group type: EXPERIMENTAL
Intervention: Line drawings with short contours removed
Number of subjects: 0
Study 19188926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedra and caffeine (E+C)
Number of subjects: 72
Study 19188926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 17713162 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC125 100 mg twice daily coadministered with DRV/r 600/100 mg twice daily
Number of subjects: 32
Study 17713162 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC125 200 mg twice daily coadministered with DRV/r 600/100 mg twice daily
Number of subjects: 32
Study 17713162 — intervention group
Group type: COMPARATOR
Intervention: DRV/r 600/100 mg twice daily
Number of subjects: 32
Study 15053373 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol alone (0.03 ml/kg/dose)
Number of subjects: 50
Study 15053373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nebulization of Salbutamol (0.03 ml/kg/dose) and Ipratropium bromide (250 microgm/dose for three doses)
Number of subjects: 50
Study 11575732 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment algorithms for treatment-resistant depression
Number of subjects: 0
Study 11575732 — intervention group
Group type: EXPERIMENTAL
Intervention: Texas Medication Algorithm Project
Number of subjects: 0
Study 11575732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequenced Treatment Alternatives to Relieve Depression
Number of subjects: 0
Study 9337491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment package including cognitive correction, problem-solving training, social skills training, and relapse prevention
Number of subjects: 29
Study 9337491 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 29
Study 7946368 — intervention group
Group type: COMPARATOR
Intervention: Plain 0.5% bupivacaine with 1:200,000 epinephrine (Group 1)
Number of subjects: 26
Study 7946368 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal 0.5% bupivacaine (Group 2)
Number of subjects: 26
Study 7946368 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 3035003 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D immunoglobulin injections at 28th and 34th weeks of pregnancy
Number of subjects: 1988
Study 3035003 — intervention group
Group type: COMPARATOR
Intervention: Control group without treatment
Number of subjects: 1988
Study 3035003 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum treatment
Number of subjects: 1988
Study 3035003 — intervention group
Group type: COMPARATOR
Intervention: Kleihauer tests at 29th week of pregnancy
Number of subjects: 1988
Study 3035003 — intervention group
Group type: COMPARATOR
Intervention: Kleihauer tests at 34th week of pregnancy
Number of subjects: 1988
Study 28903790 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Number of subjects: 10
Study 28903790 — intervention group
Group type: COMPARATOR
Intervention: Informational Pamphlet (IP)
Number of subjects: 10
Study 28711117 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Training Technique (ATT)
Number of subjects: 81
Study 28711117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Progressive Muscle Relaxation (MB‐PMR)
Number of subjects: 81
Study 28711117 — intervention group
Group type: COMPARATOR
Intervention: Thought Wandering Control (TWC)
Number of subjects: 81
Study 25596910 — intervention group
Group type: EXPERIMENTAL
Intervention: CONSORT dosing (follitropin alfa starting dose determined by the CONSORT calculator)
Number of subjects: 200
Study 25596910 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing (150 IU of follitropin alfa)
Number of subjects: 200
Study 24285276 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 1950
Study 24285276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1950
Study 24285276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 1950
Study 24285276 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at randomization
Number of subjects: 1950
Study 24285276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower bone mineral density
Number of subjects: 1950
Study 24285276 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivity
Number of subjects: 1950
Study 21955647 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy nuts, soy milk, tempeh
Number of subjects: 7
Study 21955647 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg genistein
Number of subjects: 7
Study 21955647 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pure S-(−)equol
Number of subjects: 7
Study 21955647 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy infant formula and soy germ isoflavone supplement
Number of subjects: 7
Study 21955647 — intervention group
Group type: COMPARATOR
Intervention: Soy-containing diets
Number of subjects: 7
Study 18779360 — intervention group
Group type: EXPERIMENTAL
Intervention: AS plus AQ (n = 88)
Number of subjects: 103
Study 18779360 — intervention group
Group type: COMPARATOR
Intervention: AQ only (n = 15)
Number of subjects: 103
Study 18779360 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 16574882 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS women
Number of subjects: 58
Study 16574882 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS men
Number of subjects: 58
Study 16574882 — intervention group
Group type: COMPARATOR
Intervention: Healthy women
Number of subjects: 58
Study 16574882 — intervention group
Group type: COMPARATOR
Intervention: Healthy men
Number of subjects: 58
Study 16574882 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS and control women
Number of subjects: 58
Study 14977339 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.25-0.5 microg kg(‐1) min(‐1), n = 16)
Number of subjects: 32
Study 14977339 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2-5 microg kg(‐1), n = 16)
Number of subjects: 32
Study 14977339 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 32
Study 14977339 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 32
Study 14977339 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and Fentanyl
Number of subjects: 32
Study 10707788 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic epitope for My‐La CTL
Number of subjects: 0
Study 10707788 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic epitopes
Number of subjects: 0
Study 9446300 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation
Number of subjects: 109
Study 9446300 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared pulsed laser therapy
Number of subjects: 109
Study 9446300 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin electrophoresis
Number of subjects: 109
Study 9446300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 109
Study 9446300 — intervention group
Group type: COMPARATOR
Intervention: Laser imitation (control group)
Number of subjects: 109
Study 1526696 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg and 20 mg
Number of subjects: 16
Study 1526696 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 16
Study 1526696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3886706 — intervention group
Group type: EXPERIMENTAL
Intervention: tolmetin 1,200 mg/d for three weeks
Number of subjects: 26
Study 3886706 — intervention group
Group type: COMPARATOR
Intervention: placebo for three weeks
Number of subjects: 26
Study 29137895 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-kallikrein panel (total, free, and intact PSA and hK2)
Number of subjects: 4861
Study 29137895 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-kallikrein panel plus β-microseminoprotein (MSP)
Number of subjects: 4861
Study 29137895 — intervention group
Group type: COMPARATOR
Intervention: Total PSA and age
Number of subjects: 4861
Study 27809403 — intervention group
Group type: EXPERIMENTAL
Intervention: Global evaluation after 8 hours of continuous duty
Number of subjects: 4
Study 27809403 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical evaluation after 8 hours of continuous duty
Number of subjects: 4
Study 27809403 — intervention group
Group type: EXPERIMENTAL
Intervention: Global evaluation after sufficient sleep
Number of subjects: 4
Study 27809403 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical evaluation after sufficient sleep
Number of subjects: 4
Study 27809403 — intervention group
Group type: EXPERIMENTAL
Intervention: Global evaluation on day 2 (after sleep)
Number of subjects: 4
Study 28588915 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme for associate clinicians in emergency obstetric and neonatal care
Number of subjects: 46
Study 28588915 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 46
Study 28588915 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme for associate clinicians
Number of subjects: 46
Study 25517279 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape powder (500 mg of polyphenols/day)
Number of subjects: 16
Study 25517279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23332908 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic subjects
Number of subjects: 35
Study 23332908 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with mechanical low back pain
Number of subjects: 35
Study 23332908 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with symptomatic spinal stenosis
Number of subjects: 35
Study 23332908 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with symptomatic spinal stenosis (severe)
Number of subjects: 35
Study 20447621 — intervention group
Group type: EXPERIMENTAL
Intervention: NADH 20mg
Number of subjects: 86
Study 20447621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 18983652 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-session group training combined with three individual counselling sessions
Number of subjects: 0
Study 18983652 — intervention group
Group type: COMPARATOR
Intervention: Control group (no care or care as usual)
Number of subjects: 0
Study 16887155 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange-based drinks (three types with varying sweetness intensity)
Number of subjects: 68
Study 16887155 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange peach drink (highest sugar content)
Number of subjects: 68
Study 14529097 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5-mg chewable tablet once daily)
Number of subjects: 333
Study 14529097 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn (two puffs 4 times daily)
Number of subjects: 333
Study 10634360 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (300 mg, im, every 3 weeks)
Number of subjects: 50
Study 10634360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10634360 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI treatment without protease inhibitor
Number of subjects: 50
Study 10634360 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI treatment with protease inhibitor
Number of subjects: 50
Study 9336129 — intervention group
Group type: COMPARATOR
Intervention: Standard radiation therapy with 60 Gy at 2.0 Gy per day (STD RT)
Number of subjects: 458
Study 9336129 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin 100 mg/m2 days 1 and 29 with vinblastine 5 mg/m2 weekly for 5 weeks followed by 60 Gy at 2.0 Gy per day (CT + RT)
Number of subjects: 458
Study 9336129 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiation therapy with 69.6 Gy at 1.2 Gy b.i.d. (HFX RT)
Number of subjects: 458
Study 8441078 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual palpation
Number of subjects: 27
Study 8441078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballottement palpation
Number of subjects: 27
Study 8441078 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation from above
Number of subjects: 27
Study 8441078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nixon's percussion method
Number of subjects: 27
Study 8441078 — intervention group
Group type: EXPERIMENTAL
Intervention: Castell's percussion method
Number of subjects: 27
Study 8441078 — intervention group
Group type: EXPERIMENTAL
Intervention: Barkun et al.'s percussion method
Number of subjects: 27
Study 8441078 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tests (palpation or percussion)
Number of subjects: 27
Study 2876325 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcal capsular polysaccharide vaccines
Number of subjects: 3
Study 28920542 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief risk-reducing Motivational Interviewing (MI) counselling intervention, n=74
Number of subjects: 173
Study 28920542 — intervention group
Group type: COMPARATOR
Intervention: Control group, n=99
Number of subjects: 173
Study 28920542 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief risk-reducing Motivational Interviewing (MI) counselling intervention
Number of subjects: 173
Study 28920542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 173
Study 27327441 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg)
Number of subjects: 24
Study 27327441 — intervention group
Group type: COMPARATOR
Intervention: Renal denervation (RDN)
Number of subjects: 24
Study 24218527 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNB1b 250 μg subcutaneously every other day
Number of subjects: 468
Study 24218527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 22354108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic wrist-hand orthosis (WHO)
Number of subjects: 19
Study 22354108 — intervention group
Group type: COMPARATOR
Intervention: Manual-assisted therapy (MAT)
Number of subjects: 19
Study 20138609 — intervention group
Group type: EXPERIMENTAL
Intervention: TCMF IOL
Number of subjects: 248
Study 20138609 — intervention group
Group type: COMPARATOR
Intervention: CEMN IOL
Number of subjects: 248
Study 18208849 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion-cardiac magnetic resonance (perfusion-CMR) at a dose of 0.1 mmol/kg Gd-DTPA-BMA
Number of subjects: 234
Study 18208849 — intervention group
Group type: COMPARATOR
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 234
Study 18208849 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion-cardiac magnetic resonance (perfusion-CMR)
Number of subjects: 234
Study 15931612 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef supplementation (0.6 g-protein/kg per day)
Number of subjects: 21
Study 15931612 — intervention group
Group type: COMPARATOR
Intervention: Soy-based texturized vegetable protein foods (VEG group)
Number of subjects: 21
Study 12839376 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/Kg/day; Group A, n = 12)
Number of subjects: 25